TY  - JOUR
AU  - Macher-Goeppinger, Stephan
AU  - Keith, Martina
AU  - Endris, Volker
AU  - Penzel, Roland
AU  - Tagscherer, Katrin
AU  - Pahernik, Sascha
AU  - Hohenfellner, Markus
AU  - Gardner, Humphrey
AU  - Grüllich, Carsten
AU  - Schirmacher, Peter
AU  - Roth, Wilfried
TI  - MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
JO  - OncoTarget
VL  - 8
IS  - 1
SN  - 1949-2553
CY  - [S.l.]
PB  - Impact Journals LLC
M1  - DKFZ-2017-00062
SP  - 1046-1057
PY  - 2017
AB  - Multiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17
LB  - PUB:(DE-HGF)16
C6  - pmid:27894094
DO  - DOI:10.18632/oncotarget.13540
UR  - https://inrepo02.dkfz.de/record/119276
ER  -